• ViroGates’ Q1-Q3 2026 net loss narrowed 29% year over year to DKK 5.68 million.
• Revenue climbed 75% to DKK 6.21 million, driven largely by U.S. partner orders in Q2.
• Following an FDA request for additional information on suPARnostic TurbiLatex, ViroGates and Sobi are preparing clinical and analytical data.
• The commercial strategy shifted toward larger, scalable partnerships, with a review of the existing partner portfolio underway.
• Full-year 2026 guidance remains revenue of DKK 6.5 million–DKK 8 million and an EBIT loss of DKK 10 million–DKK 12 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ViroGates A/S published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.